SynthesisEuropean journal of drug metabolism and pharmacokinetics2026
The Influence of CBD and THC on Hepatic Enzymes of the Human Cytochrome P450 Complex Family: A Systematic Literature Review.
Synthesis in European journal of drug metabolism and pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cytochrome P450-Catalyzed Hydroxylation of Δ8-Tetrahydrocannabinol and Implications for Pharmacogenetics.Pharmaceutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivePhytocannabinoids, the main bioactive compounds of Cannabis sativa, are metabolized by hepatic cytochrome P450 (CYP450) enzymes and can also modulate their function. Since CYP450 isoforms are responsible for the metabolism of approximately 80% of therapeutic drugs, interactions between phytocannabinoids and these enzymes may have clinically relevant consequences. The objective of this systematic review was to systematically evaluate the effects of phytocannabinoids on the activity and expression of hepatic CYP450 complex enzymes.
methodsThis systematic review was conducted according to PRISMA guidelines. Literature searches were performed in PubMed, SciELO, ScienceDirect, and Scopus, covering studies published between January 2019 and March 2025. In vitro, in vivo, or ex vivo studies that evaluated the modulatory effects of phytocannabinoids on hepatic CYP450 isoforms were included. After applying the inclusion and exclusion criteria, four studies met the eligibility requirements.
resultsThe selected studies reported that phytocannabinoids, particularly cannabidiol (CBD), exert inhibitory effects on several CYP450 isoforms, including CYP3A4, CYP2C9, and CYP2C19. One study indicated that CYP2C19 activity could also be induced under certain conditions. In contrast, CYP2D6 showed minimal or no modulation. Overall, CBD was consistently identified as a potent inhibitor of CYP enzymes responsible for drug metabolism.
conclusionPhytocannabinoids, particularly CBD, influence the activity of key CYP450 system enzymes, predominantly through inhibition. These findings highlight the potential for drug-cannabinoid interactions and emphasize the need for additional clinical and mechanistic studies to assess safety and pharmacokinetic implications in patients using cannabis-based therapies.
Indexed as
Identifiers
41417208What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.